Related Experiment Video
Updated: Jun 3, 2026
06:21
Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
Published on: November 19, 2019
Phase IIA trial testing erlotinib as an intervention against intraductal pancreatic mucinous neoplasms
Steven Lipkin1, John Lee, David Imagawa
1Department of Medicine and Chao Family NCI Designated Comprehensive Cancer Center, University of California Irvine, Irvine, California, USA. stl2012@med.cornell.edu
Cancer Prevention Research (Philadelphia, Pa.)
|April 6, 2011
Abstract:
Intraductal papillary mucinous neoplasms (IPMN) are a distinct type of precursor lesions that cause about 5% of pancreatic adenocarcinoma (1, 2). Four-year survival rates of 40% to 75% are reported (3-7). There is currently no chemotherapy specifically approved for treating IPMNs. The number of IPMN cases has significantly increased over the last decade (8).
